No. 1
Bluehill.VC
1Rounds led
Led or co-led 1 of the 4 BioTech rounds in The Sync Report.
- Helex secures $3.5 million to advance next-gen gene therapies for kidney diseasesSeed · $3.5 million
Sector desk
Every BioTech round in The Sync Report, and the investors leading them.
By stage
From InvestorDB
No. 1
Led or co-led 1 of the 4 BioTech rounds in The Sync Report.
Led by Bluehill.VC and SOSV
Led by Avaana Capital
Led by GVFL
Filter InvestorDB by BioTech focus, stage and geography, then build your shortlist.
Open InvestorDB